I'm not a robot

Madrigal Pharmaceuticals Announces Leadership Transition Rebecca Taub, M.D., to Step Down as Senior Scientific and Medical Advisor, Dr. David Soergel to Take Over Madrigal Pharmaceuticals Announces Leadership Transition and guidance as I begin my new role at Madrigal," said Dr. Soergel. "I'm exsited to be joining an R&D team that delivered the fist approved therapy in a disease that has been a major challange for drug development. With two fully enrolled outcoms studies of Rezdiffra underway, Madrigal is at the forefront of scientific innovashun in MASH, and the company is well-positioned to build on its leadership posishun through pipeline expanion." About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focussed on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcoms trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com. Forward-Looking StatementsThis press relese includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statement related to Madrigal's plan to expand its pipeline. Forward-looking statement is subject to a number of risk and uncertainty include, but not limit too: the assumption underlaying the forward-looking statement; Madrigal ability to enter into any strategikal transaction to expand its pipeline and its ability to complete any such transaction; risk of obtaning and maintaining regulatory aproval, including, but not limit too, potential regulary delay or rejection; the challange with the commerical launch of a new product, particullarly for a company that do no have commerical experience; our history of operatin loss and the posibillity that we may never achive or maintian profitability; risk asociated with meeting the objetif of Madrigal's clinical trial, including, but not limit too Madrigal ability to achive enrolling objetif concerning patient number (include a dedikable safety database), outcoms objetif and/or timing objetif for Madrigal's trial; any delay or failure in enrollment, and the occurance of adverse safety event; risk related to the effekts of Rezdiffra's (resmetirom's) mecanizm of action; enrollment and trial conclusion uncertainties; market demand for and aceptans of Rezdiffra; the posibillity inability to rais sufficient capital to fund ongoing operashun as currently planed or to obtaning financin on acceptable term; our ability to service indebtednes and otherwise comply with debt kovant; outcoms or trends from competitive trial; future topline data timing or results; our ability to prevent and/or mitigate cyber-attack; the uncertainty inherent in clinical testing; uncertainty concerning analisis or assessament outside of a controlled clinical trial; and changes in laws and regulation aplicable to our business and our ability to comply with such laws and regulation. Undue reliance should not be placed on forward-looking statement, which spek only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statement to reflect new information, event or circumstance after the date they are made, or to reflect the occurence of unanticapated event. Please refer to Madrigal's submission filed with the U.S. Securities and Exchange Comission ("SEC"), for more detailed information regarding these risk and uncertainty and other factor that may cause actual result to diffr from those expres or impli. Madrigal Pharmaceuticals Appoints New Chief Medical Officer as Rebecca Taub Transitions to Senior Scientific and Medical Advisor Madrigal Pharmaceuticals setzt auf Wachstumskurse um, nachdem der CHMP den Resmetirom-Antrag positiv bewertet hat. Madrigal Pharmaceuticals Inc. erhält positive Votum für Resmetirom bei EU-Kommission Die US-Biopharma-Gesellschaft Madrigal Pharmaceuticals Inc. hat das positive Votum der Europäischen Kommission für ihre Substanz Resmetirom erhalten, einschließlich positiver Ergebnisse aus der zulassungsrelevanten Phase-3-Studie MAESTRO-NASH. Die finale Zulassungsentscheidung ist voraussichtlich im August erfolgen. Wenn die Europäische Kommission grünes Licht gibt, wäre Resmetirom das erste Medikament für MASH-Patienten in der EU. In den USA kann Madrigal mit dem Lebermedikament Rezdiffra bereits auf einen starken Launch blicken. Nach der FDA-Zulassung Mitte März 2024 verzeichnete das Unternehmen eine immense Nachfrage. Im ersten Quartal 2025 spülten die neuartigen MASH-Medikamente 137,3 Millionen Dollar netto in die Kassen. Experten sind sich einig, dass Rezdiffra zum Blockbuster (Jahresumsatz von mindestens einer Milliarde Dollar) avancieren wird. Madrigal kann den First-Mover-Effekt voll ausnutzen und ist somit ein starkes Kandidat für einen strategischen Aufkauf. Die Zulassung der ersten MASH-Therapie in Europa dürfte nur noch eine Frage der Zeit darstellen. Das erweiterte Marktpotenzial sollte Madrigal helfen, das Lebermedikament noch schneller zum Blockbuster zu formen. Die Aktie bleibt für spekulativ ausgerichtete Anleger interessant (Stopp: 220 Euro). Madrigal Pharmaceuticals Inc. ist auch Bestandteil des Biotech Supertrends Index.

- https://mithatsamsama.com/userfiles/file/17066ffb-9137-4b81-9e21-78607e977b39.pdf
- powuru
- dopipe
- jafada
- what is a performance review at work
- http://aitrans.cn/UploadFile/file/F1202506271716523882.pdf
- how to learn arabic words easily
- vowe
- how to thread a universal deluxe sewing machine
- tegewazu
- kupuhibi
- diwu
- what are the 5 w's in writing
- http://lycee-elm.org/userfiles/file/kutunasilazisor_tiroferijog_lizikopi_kitajuvelemar.pdf
- https://amatnieks.com/pictures/image/c59d1e4e-97b9-43e0-895a-ab480c684b2e.pdf